Press Contact
For media enquiries, please reach out to: contact@aspivix.com
All
- All
- Blog
- In the media
- Press releases
Aspivix mentioned in MD+DI – “Removing the Pain from ‘Just a Little Pinch’ Gynecological Procedures”
Read the MD+DI (Medical Device and Diagnostic Industry) article here
Aspivix Featured in Forbes France Following Top 10 Placement at Inaugural MedFemTech Congress
Renens, Switzerland – 10 May 2023 – ASPIVIX SA, a leading Swiss startup in women's healthcare, is thrilled to announce its feature in Forbes France after securing a spot in the top...
ASPIVIX Announces That Contraception, an International Reproductive Health Journal, Has Published First-In-Women Results Using Novel Cervical Stabilizer In IUD Procedures
Renens, Switzerland – 13 March 2023 – ASPIVIX SA, an innovator and developer of medical technologies to advance gynecological and fertility care, today announced the publication of the results in Contraception, an...
Aspivix receives U.S. FDA 510(k) Clearance for Carevix®, Their Novel Cervical Stabilizer
Renens, Switzerland – 26 January 2023 – ASPIVIX SA, an innovator and developer of medical technologies to advance gynecological care, today announced that Carevix®, its novel Atraumatic Cervical Stabilizer, has received 510(k)...
Aspivix mentioned in Femtech World about Serie A
Read the Femtech World article here
ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.
This funding round will accelerate market access in Europe and US, and finance clinical activities in the US, while the EUREKA EUROSTARS grant will fuel R&D’s activities to expand product offering. ASPIVIX,...
